Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy ContraFect Corporation (CFRX) stocks in Canada

Learn how to easily invest in ContraFect Corporation stocks.

ContraFect Corporation is a biotechnology business based in the US. ContraFect Corporation stocks (CFRX.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $4.58 – a decrease of 6.35% over the previous week. ContraFect Corporation employs 33 staff and has a market cap (total outstanding stock value) of $99.1 million.

How to buy shares in ContraFect Corporation

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CFRX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

ContraFect Corporation stock price (NASDAQ:CFRX)

Use our graph to track the performance of CFRX stocks over time.

ContraFect Corporation shares at a glance

Information last updated 2022-01-17.
Latest market close$2.36
52-week range$2.37 - $7.63
50-day moving average $3.04
200-day moving average $3.74
Wall St. target price$13.58
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.66

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of $200+/month. Valid until March 1, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy ContraFect Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

ContraFect Corporation price performance over time

Historical closes compared with the close of $2.36 from 2022-01-21

1 week (2022-01-14) -6.35%
1 month (2021-12-22) -11.61%
3 months (2021-10-22) -38.38%
6 months (2021-07-23) -40.25%
1 year (2021-01-22) -55.81%
2 years (2020-01-23) 110.71%
3 years (2019-01-23) 353.85%
5 years (2017-01-23) 34.86%

ContraFect Corporation financials

Gross profit TTM $-1,606,434
Return on assets TTM -39.8%
Return on equity TTM -62.43%
Profit margin 0%
Book value $1.35
Market capitalisation $99.1 million

TTM: trailing 12 months

ContraFect Corporation share dividends

We're not expecting ContraFect Corporation to pay a dividend over the next 12 months.

Have ContraFect Corporation's shares ever split?

ContraFect Corporation's shares were split on a 1:10 basis on 3 February 2020. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your ContraFect Corporation shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for ContraFect Corporation shares which in turn could have impacted ContraFect Corporation's share price.

ContraFect Corporation share price volatility

Over the last 12 months, ContraFect Corporation's shares have ranged in value from as little as $2.37 up to $7.63. A popular way to gauge a stock's volatility is its "beta".

CFRX.US volatility(beta: 0.76)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ContraFect Corporation's is 0.7572. This would suggest that ContraFect Corporation's shares are less volatile than average (for this exchange).

ContraFect Corporation overview

ContraFect Corporation, a clinical-stage biotechnology company, focuses on the discovery and development of therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead product candidates consist of CF-301, an investigational novel lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible. The company also develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staph aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis; and CF-370, an investigational anti-bacterial therapeutic candidate, which in preclinical trials for the treatment of pseudomonas aeruginosa infections, including ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. The company has a collaboration research agreement with The Rockefeller University to identification of novel lysin therapeutic candidates targeting gram-negative pathogens. It also initiated an expanded access program to provide exebacase for the treatment of persistent bacteremia caused by methicillin-resistant Staphylococcus aureus in COVID-19 patients. The company was incorporated in 2008 and is headquartered in Yonkers, New York. .

Stocks similar to ContraFect Corporation

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site